glp-1 agonist and gastroparesis How Dangerous Is Gastroparesis? Gastroparesis: Symptoms, Causes, Diagnosis &
Description
Starting Wednesday, Medicare will help pay for some GLP-1 medications for weight loss
no major safety concerns were observed
David Kessler says the new weight-loss drugs are a powerful tool to fight obesity
Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027
Metseras pipeline includes MET-097i, a GLP-1 receptor agonist designed for once-monthly dosing, and MET-233i, an amylin analog being developed for monthly administration
Early tight control reduces long-term vascular risk
